Antiviral and adjuvant activity of immunomodulator adamantylamide dipeptide.
Masihi
K N
KN
Robert Koch Institute, Federal Health Office, Berlin, FRG.
Rohde-Schulz
B
B
Masek
K
K
Palache
B
B
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000547:Amantadine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D000998:Antiviral Agents / Q000494:pharmacology*; D004151:Dipeptides / Q000008:administration & dosage / Q000494:pharmacology*; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D007252:Influenza Vaccines / Q000008:administration & dosage; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000517:prevention & control
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D000998:Antiviral Agents; D004151:Dipeptides; D007252:Influenza Vaccines; C044891:adamantylamide-alanyl-isoglutamine; D000547:Amantadine